tert-butyl 2-(1-methyl-1H-imidazol-4-yl)ethylcarbamate | 200941-95-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: tert-butyl 2-(1-methyl-1H-imidazol-4-yl)ethylcarbamate
• 英文别名: [2-(1-methyl-1H-imidazol-4-yl)-ethyl]-carbamic acid tert-butyl ester；tert-butyl N-[2-(1-methylimidazol-4-yl)ethyl]carbamate
• CAS: 200941-95-3
• 化学式: C₁₁H₁₉N₃O₂
• 分子量: 225.291
• InChiKey: UAVBHJDVZOWDSC-UHFFFAOYSA-N

物化性质

• 沸点：
  409.4±28.0 °C(Predicted)
• 密度：
  1.08±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  16
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.64
• 拓扑面积：
  56.2
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  tert-butyl 2-(1-methyl-1H-imidazol-4-yl)ethylcarbamate 在 N-氯代丁二酰亚胺 作用下， 以 乙腈 为溶剂， 以59%的产率得到
  参考文献：
  名称：

  2-(1H-Imidazol-4-yl)ethanamine and 2-(1H-pyrazol-1-yl)ethanamine side chain variants of the IGF-1R inhibitor BMS-536924

  摘要：

  A series of IGF-1R inhibitors is disclosed, wherein the (m-chlorophenyl) ethanol side chain of BMS-536924 (1) is replaced with a series of 2-(1H-imidazol-4-yl)ethanamine and 2-(1H-pyrazol-1-yl)ethanamine side chains. Some analogs show improved IGF-1R potency and oral exposure. Analogs from both series, 16a and 17f, show in vivo activity comparable to 1 in our constitutively activated IGF-1R Sal tumor model. This may be the due to the improved protein binding in human and mouse serum for imidazole 16a and the excellent oral exposure of pyrazole 17f. (C) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2008.01.049
• 作为产物：
  描述：

  histamine dichloride 在 sodium hydride 、 sodium hydroxide 作用下， 以 1,4-二氧六环 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 6.0h， 生成 tert-butyl 2-(1-methyl-1H-imidazol-4-yl)ethylcarbamate
  参考文献：
  名称：

  Facile Syntheses of Histamine- and Imidazole-4-propionic Acid–Derived Room-Temperature Ionic Liquids

  摘要：

  We report synthesis of histamine- and imidazole-4-propionic acid-based ionic liquids containing a variety of alkyl and aryl groups placed at the two different positions of the constituent imidazole ring in convenient steps in good yields.

  DOI：

  10.1080/00397911.2011.555053

文献信息

• CXCR4 chemokine receptor binding comounds
  申请人：——

  公开号：US20040209921A1

  公开（公告）日：2004-10-21

  The present invention relates to compounds that bind to chemokine receptors, and having the formula 1 wherein each A, X, Y, R 1 , R 2 and R 3 are substituents. The present invention also relates to methods of using such compounds, such as in treating HIV infection and inflammatory conditions such as rheumatoid arthritis. Furthermore, the present invention relates to methods to elevate progenitor and stem cell counts, as well as methods to elevate white blood cell counts, using such compounds.

  本发明涉及与趋化因子受体结合的化合物，其具有式1的结构，其中A、X、Y、R1、R2和R3均为取代基。本发明还涉及使用这类化合物的方法，例如在治疗HIV感染和炎症性疾病如类风湿性关节炎中的应用。此外，本发明还涉及使用这类化合物来提高祖细胞和干细胞计数的方法，以及提高白细胞计数的方法。
• CXCR4 CHEMOKINE RECEPTOR BINDING COMPOUNDS
  申请人：BRIDGER Gary J.

  公开号：US20080255197A1

  公开（公告）日：2008-10-16

  The present invention relates to compounds that bind to chemokine receptors, and having the formula wherein each A, X, Y, R 1 , R 2 and R 3 are substituents. The present invention also relates to methods of using such compounds, such as in treating HIV infection and inflammatory conditions such as rheumatoid arthritis. Furthermore, the present invention relates to methods to elevate progenitor and stem cell counts, as well as methods to elevate white blood cell counts, using such compounds.

  本发明涉及与趋化因子受体结合的化合物，其具有以下式子： 其中每个A、X、Y、R1、R2和R3均为取代基。本发明还涉及使用这种化合物的方法，例如用于治疗HIV感染和炎症性疾病，如类风湿性关节炎。此外，本发明还涉及使用这种化合物提高祖细胞和干细胞数量的方法，以及提高白细胞计数的方法。
• CXCR4 chemokine receptor binding compounds
  申请人：Genzyme Corporation

  公开号：US07291631B2

  公开（公告）日：2007-11-06

  The present invention relates to compounds that bind to chemokine receptors, and having the formula wherein each A, X, Y, R1, R2 and R3 are substituents. The present invention also relates to methods of using such compounds, such as in treating HIV infection and inflammatory conditions such as rheumatoid arthritis. Furthermore, the present invention relates to methods to elevate progenitor and stem cell counts, as well as methods to elevate white blood cell counts, using such compounds.

  本发明涉及结合趋化因子受体的化合物，其具有以下式子： 其中每个A、X、Y、R1、R2和R3均为取代基。本发明还涉及使用这种化合物的方法，例如用于治疗HIV感染和炎症性疾病，如类风湿性关节炎。此外，本发明还涉及使用这种化合物提高祖细胞和干细胞计数的方法，以及提高白细胞计数的方法。
• EP1613613A4
  申请人：——

  公开号：EP1613613A4

  公开（公告）日：2009-03-25
• EP1613613A2
  申请人：——

  公开号：EP1613613A2

  公开（公告）日：2006-01-11